Bear bile inhibits the immunosuppression activity of hepatic stellate cells in vivo

Hepato-Gastroenterology

Volumn 59, Issue 117, 2012, Pages 1529-1536

  Zhou, Chang Sheng ^a,b   Yin, Zhen Yu ^b   Zhao, Wen Xiu ^b   Zhang, Lei ^b   You, Jun Yong ^b,c   Su, Wei Xue ^b   Fan, Jia ^d   Wang, Xiao Min ^b  

^a Guizhou Province People's Hospital   (China)

^b ZHONGSHAN HOSPITAL OF XIAMEN UNIVERSITY   (China)

^c FUJIAN MEDICAL UNIVERSITY   (China)

^d ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Bear bile; Chronic liver disease; Hepatic stellate cells; Immune; Inhibition

Indexed keywords

BEAR BILE; CHINESE DRUG; CYTOKINE; NATURAL PRODUCT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEAR; BILE; CHINESE MEDICINE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; ENDANGERED SPECIES; FEEDING; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LD 50; LIVER CELL CULTURE; LIVER DISEASE; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; STELLATE CELL; T LYMPHOCYTE; TRADITIONAL MEDICINE;

ACTINS; ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; BILE; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DESMIN; HEPATIC STELLATE CELLS; IMMUNE TOLERANCE; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES, REGULATORY; URSIDAE;

EID: 84865180829     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10637     Document Type: Article

References (31)

1. Llovet J M, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362:1907-1917.
2. Thimme R, Neagu M, Boettler T, et al.: Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T-cell responses in patients with hepatocellular carcinoma. Hepatology 2008; 48:1821-1833.
3. Nakamoto Y, Kaneko S: Dendritic cell-based immunotherapy for hepatocellular carcinoma. Can To Kagaku Ryoho 2010; 37:413-416.
4. Ladhams A, Schmidt C, Sing G, et al.: Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 2002; 17:889-896.
5. Takayama T, Sekine T, Makuuchi M, et al.: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356:802-807.
6. Zou W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263-274.
7. Knolle PA, Gerken G: Local control of the immune response in the liver. Immunol Rev 2000; 174:21-34.
8. Yu MC, Chen CH, Liang X, et al.: Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology 2004; 40:1312-1321.
9. Feng Y, Siu K, Wang N, et al.: Bear bile: dilemma of traditional medicinal use and animal protection. J Ethnobiol Ethnomed 2009; 5:2.
10. Quan MJ, Jin RS, Piao L, Piao DM: Inhibitory effects of bear bile powder on dimethylnitrosamine-induced liver fibrosis in rats. World Chin J Digestol 2005; 13:2487-2490 (In Chinese with English abstract).
11. Steiling H, Muhlbauer M, Bataille F, et al.: Activated hepatic stellate cells express keratinocyte growth factor in chronic liver disease. Am J Pathol 2004; 165:1233-1241.
12. Yang HR, Hsieh CC, Wang L, et al.: A critical role of TRAIL expressed on cotransplanted hepatic stellate cells in prevention of islet allograft rejection. Microsurgery 2010; 30(4):332-337.
13. Ohta S, Ueda Y, Yaguchi M, et al.: Isolation and characterization of dendritic cells from common marmosets for preclinical cell therapy studies. Immunology 2008; 123:566-574.
14. Yamamoto K, Sargent PA, Fisher MM, Youson JH: Periductal fibrosis and lipocytes fat-storing cells or Ito cells during biliary atresia in the lamprey. Hepatology 1986; 6:54-59.
15. Ballardini G, Groff P, Badiali de Giorgi L, Schuppan D, Blanchi FB: Ito cell heterogeneity: desmin-negative Ito cells in normal rat liver. Hepatology 1994; 19:440-446.
16. Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6:295-307.
17. Friedman SL: Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993; 328:1828-1835.
18. Hellerbrand, Wang SC, Tsukamoto H, Brenner DA, Rippe RA: Expression of intracellular adhesion molecule 1 by activated hepatic stellate cells. Hepatology 1996; 24:670-676.
19. Yin Z, Jiang G, Fung JJ, Lu L, Qian S: ICAM-1 expressed on hepatic stellate cells plays an important role in immune regulation. Microsurgery 2007; 27:328-332.
20. Manzotti CN, Liu MK, Burke F, Dussably L, Zheng Y, Sanson DM: Integration of CD28 and CTLA-4 function results in differential responses of T cells to CD80 and CD86. Eur J Immunol 2006; 36:1413-1422.
21. Okazaki T, Honjo T: PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 19:813-824.
22. Keir ME, Butte MJ, Freeman GJ, Sharpe AH: PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol 2008; 26:677-704.
23. Dong H, Strome SE, Salomao DR, et al.: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8:793-800.
24. Amann T, Bataille F, Spruss T, et al.: Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci 2009; 100:646-653.
25. Theret N, Musso O, Turlin B, et al.: Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 2001; 34:82-88.
26. Van Snick J, Houssiau F, Proost P, Van Damme J, Renauld JC: I-309/T-cell activation gene-3 chemokine protects murine T-cell lymphomas against dexamethasone-induced apoptosis. J Immunol 1996; 157:2570-2576.
27. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP: Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74:111-122.
28. Kawamata H, Kawai K, Kameyama S, et al.: Over-expression of tissue inhibitor of matrix metalloproteinases TIMP1 and T1MP2 suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Int J Cancer 1995; 63:680-687.
29. Dienz O, Rincon M: The effects of IL-6 on CD4 T-cell responses. Clin Immunol 2009; 130:27-33.
30. Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L: Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer 2009; 125:1640-1648.
31. Ghirtnghelli F, Menard C, Puig PE, et al.: Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641-648.